Background {#Sec1}
==========

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease resulting in an inability to control glucose homeostasis due to insulin resistance. It accounts for over 90 % of all diabetes cases \[[@CR1]\], and in many western countries it is reaching epidemic proportions due to an ageing population, increasing prevalence of obesity and sedentary lifestyles \[[@CR2]\]. There are several clinical complications associated with diabetes which include macro- and micro-vascular disorders such as stroke, coronary heart disease, peripheral vascular disease as well as nephropathy and retinopathy \[[@CR3]\]. These conditions can impose an immense burden on the quality of life of individuals with diabetes \[[@CR4]\].

The systemic nature of atherosclerosis is widely appreciated with disease in one arterial territory predictive of disease in another, with this effect particularly pronounced in diabetes \[[@CR5]\]. Thus the ability to assess the whole body burden of this disease process is desirable in an effort to greater understand macro-vascular disease burden and behaviour in diabetes, as well as to help quantify future risk, target treatments and monitor response. Whole body cardiovascular magnetic resonance imaging (WB CVMR) combines cardiac magnetic resonance (CMR) and whole body MR angiography (WB-MRA) sequences to produce high spatial and temporal resolution images of the cardiovascular system with coverage from the head to the feet \[[@CR6]\]. It has been shown to be effective at systemically quantifying the presence and severity of cardiac disease and atherosclerosis across the arterial network in patients with cardiovascular disease in single examination taking of the order of 45 min \[[@CR7]\]. WB-MRA in a diabetic population has been previously demonstrated to be a feasible single examination for ascertaining cardiovascular disease distribution, detecting occult disease and quantifying stenotic burden, and for these findings to provide strong prognostic information of future cardiovascular events \[[@CR8], [@CR9]\].

While previous studies have documented the burden of vascular disease in people with diabetes, to date no study has focussed on the impact of type 2 diabetes on the whole body atheroma burden combining quantitative of both WB-MRA and CMR. Thus we aimed to compare the effects of type 2 diabetes and individuals without CVD on the quantitative atherosclerotic burden throughout the body in those with and without known cardiovascular disease.

Methods {#Sec2}
=======

Ethical approval {#Sec3}
----------------

The East of Scotland Research Ethics Committee approved the protocols. The study was conducted at in accordance with the Declaration of Helsinki. The volunteers gave written informed consent to participate in this study.

Participants {#Sec4}
------------

The study was a single centre observational sub-study of the multicentre SUrrogate markers for Micro- and Macrovascular hard endpoints for Innovative diabetes Tools (SUMMIT) study. 158 volunteers were recruited, with 148 completing the WB-CVMR protocol between March 2009 and December 2012.

The participants were recruited from the UK Type 2 Diabetes Case--Control Collection Wellcome study and via the Scottish Primary Care Research network, the Scottish Diabetes Research network, Secondary Care Diabetes clinics, and through advertising such as posters and leaflets. After clinical evaluation, the subjects were categorised into four groups based on their history of type 2 diabetes and cardiovascular disease as follows: *Group 1* type 2 diabetes mellitus (T2DM) with a prior clinical diagnosis of cardiovascular disease that included coronary artery disease (CAD), cerebrovascular disease and/or lower extremity arterial disease (LEAD); *Group 2* type 2 diabetes mellitus with no clinical evidence of cardiovascular disease; *Group 3* absence of diabetes mellitus with clinical evidence of CAD, cerebrovascular disease and/or LEAD; *Group 4* healthy controls, with no biochemical evidence of diabetes mellitus (see below) and no clinical evidence of cardiovascular disease.

The inclusion criteria for Groups 1 and 2 (with T2DM) was T2DM diagnosis after the age of 35 and no requirement for insulin injection for 12 months after diagnosis. The non-diabetic status of those in Groups 3 and 4 were confirmed by testing their haemoglobin A1C (HbA1C) levels, with inclusion criteria requiring levels of \<6.5 % (48 mmol/ml). Coronary arterial disease inclusion criteria were non-fatal acute myocardial infarction, hospitalised acute coronary syndrome, resuscitated cardiac arrest (not attributed to non CAD causes), coronary artery bypass graft (CABG) or any other coronary revascularisation procedure. Cerebrovascular disease inclusion criteria were non-fatal strokes and transient ischemic attacks (TIA) confirmed by a specialist stroke physician. It excluded TIA not confirmed by specialist, haemorrhagic stroke, and stroke associated with a primary haematological disease e.g. leukaemia, polycythaemia, blood disease, tumours, trauma or surgical procedures. Lower extremity arterial disease (LEAD) inclusion criteria were clinical intermittent claudication with either ankle-brachial pressure index (ABPI) \<0.9, abnormal toe systolic pressure, pulse volume recordings, transcutaneous oxygen measurements, vascular imaging, or prior corrective surgery, angioplasty or above ankle amputation (see Additional file [1](#MOESM1){ref-type="media"}: Table S1 for tabulated inclusion criteria for the cardiovascular disease groups). Exclusion criteria included the presence of metallic implants, history of claustrophobia, pregnancy, renal replacement or eGFR \<30 ml/min/1.73 m^2^, and therapy for any chronic inflammatory disease, atrial fibrillation or malignancy.

Magnetic resonance imaging {#Sec5}
--------------------------

Images were acquired on a 32 RF receiver channel, 3 Tesla MRI scanner (Magnetom Trio, Siemens, Erlangen, Germany). For whole body coverage, a combination of six RF coils including head matrix, neck matrix, spine matrix, two body matrix and peripheral angiography phased array RF surface coils were used. Subjects where placed supine, head first into the magnet bore. The imaging protocol was carried out in three phases: (1) MRA of the thoracic and neck, and distal lower limbs, (2) CMR including late gadolinium enhancement (LGE) and (3) MRA of the abdomen, pelvis and proximal lower limb.

### Whole body magnetic resonance angiography protocol {#Sec6}

Whole body magnetic resonance angiography (WB-MRA) images involved the acquisition of four overlapping 3D data sets using a coronal spoiled FLASH sequence (repetition time TR = 2.6--3.47 ms; echo time TE = 0.96--1.21 ms; flip angle = 16°--37°; pixel area = 1.1--1.5 mm^2^ and slice thickness = 1--1.4 mm, slight variation according to station and participant body habitus). Anatomical paired images were acquired pre- and post-contrast from four anatomically distinct stations---head, neck and thorax (station 1), abdomen and pelvis (station 2), upper legs (stations 3) and lower legs (station 4). 0.5 M gadoterate meglumine (Guerbet, Villepinte, France) was administered by intravenous injection into antecubital fossa using a Spectris Solaris power injector (MedRad, Pittsburgh, USA) at a rate of 1.5 ml/s, followed by a 20 ml bolus of saline. A dual injection, two stage acquisition with uptitring of contrast volume was performed due to the benefits of this technique on image quality over a single injection technique \[[@CR10], [@CR11]\]. Stations 1 and 4 pre-contrast images were acquired following which post-contrast images were acquired after an injection of 10 ml gadoterate meglumine with a 20 ml saline flush, both administered at 1.5 ml/s. Cardiac MRI was performed after this first injection before stations 2 and 3 image acquisition began. Pre contrast images were acquired of both stations following which post-contrast images were acquired after an injection of 15 ml gadoterate meglumine and 20 ml saline flush administered at 1.5 ml/s.

### Cardiac magnetic resonance (CMR) protocols {#Sec7}

Cardiac magnetic resonance (CMR) imaging utilised a spine matrix and six-element body array matrix RF coils. TurboFLASH two-chamber, four-chamber and short axis localiser, and two-chamber and four-chamber cine images were acquired. Left ventricular assessment involved the acquisition of a horizontal long axis, vertical long axis and stacked short axis cine images with repeated end-expiratory breath-holds, from the atrio-ventricular ring to the apex. These were acquired using a CINE TrueFISP sequence with retrospective ECG-gating (repetition time TR = 3.4 ms; echo time TE = 1.48 ms; flip angle = 50°--60°; pixel area = 1.4 mm × 1.9 mm; slice thickness = 6 mm; inter-slice gap = 4 mm). Ten minutes after the injection of the first dose of contrast agent the LGE images were acquired using a 2D phase sensitive inversion recovery (PSIR) sequence (repetition time TR = 846.4/5.21 ms; echo time TE = 1.99 ms; flip angle = 20^0^; pixel area = 1.4 mm × 1.9 mm; slice thickness = 6 mm; inter-slice gap = 4 mm). The mean inversion time (TI) was 376 ms (range 300--450 ms).

### WB-MRA image analysis {#Sec8}

The 3D WB-MRA datasets were viewed offline (Carestream PACS Client Suite Version 10.1 sp1, Rochester, NY, USA) as source images using both multi-planar reconstruction (MPR) and maximum intensity projections (MIP) by a radiologist (JRWM) with experience of reporting over 400 whole body magnetic resonance angiograms. The radiologist was blinded to the participants' clinical history during image analysis. The arterial network was divided into 31 vessel segments extending from the distal internal carotid arteries to the distal points of the calf vessels (Fig. [1](#Fig1){ref-type="fig"}). Each arterial segment was visually inspected and assessed as either 'diagnostic' or 'non-diagnostic' depending on image quality and the clarity of vascular structure. Non-diagnostic segments were assigned as non-interpretable. The diagnostic segments were scored according to the degree of narrowing of the lumen diameter, with stenosis graded at the narrowest part of the vessel. Where more than one stenosis was present in any vessel, the most severe stenosis was used to score the vessel. Categorical scores from 0 to 4 were allocated to each vessel segment, where 0, segment with no stenosis; 1, \<50 % stenosis; 2, 51--70 % stenosis; 3, 71--99 % stenosis; 4, vessel occlusion (Fig. [2](#Fig2){ref-type="fig"}). The 'standardised atheroma score' (SAS) was calculated by summing each individual segment's stenosis score, and divided by the number of diagnostic segments (n) before dividing by 4 which is the maximum potential score (Eq. [1](#Equ1){ref-type=""}): \[[@CR7], [@CR12]\].Fig. 1Whole body angiogram with stations and vascular territories describedFig. 2MRA visualization of the iliac arteries demonstrating examples of each of the five categorical vessel scores. **a** Grade 0. **b** Grade 1---diffuse irregularity of the vessel wall, none of which is causing \>50 % stenosis. **c** Grade 2---50--70 % stenosis in the proximal external iliac. **d** Grade 3---\>70 % stenosis in the common iliac. **e** Grade 4---complete occlusion of the external iliac just after the bifurcation of the common iliac with compensatory dilation of the internal iliac artery evident$$\documentclass[12pt]{minimal}
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The 31 vessel segments were subdivided into five anatomical territories: (1) the head and neck arteries, (2) the aorta, (3) the abdominal arteries, (4) the ilio-femoral arteries and (5) Popliteal and infrageniculate arteries (Fig. [1](#Fig1){ref-type="fig"}). Regional SASs were calculated for each anatomical territory.

20 datasets were chosen at random and rescored by the same observer to derive intra-observer agreement.

### CMR image analysis {#Sec9}

Left ventricular analysis images were analysed offline using Argus software (Siemens, Erlangen, Germany) by an experienced researcher (SZM). Segmentation involved tracing endocardial and epicardial contours on the short-axis left ventricle images at end-diastolic and end-systolic phases of the cardiac cycle. Papillary muscles were treated as part of the blood pool volume unless they were indistinguishable from the myocardial wall, and then they were assigned as left ventricle muscle. The left ventricular mass (LVM), stroke volume (LVSV), ejection fraction (LVEF), end-diastolic (LVEDV) and end-systolic volumes (LVESV) were determined using algorithm based on the Simpson rule. Results were normalised to body surface area using the DuBois formula \[[@CR13]\]. Left ventricular mass volume ratio (LVMVR) was calculated as LVEDV/LVM. Left ventricular global function index (LVGFI) was calculated as LVGFI = (LVSV/LV global volume) × 100, where LV global volume was defined as the sum of the LV mean cavity volume \[(LVEDV + LVESV)/2\] and the myocardium volume \[[@CR14]\]. The PSIR sequences of the left ventricle were inspected for evidence of late gadolinium enhancement (LGE) using an imaging workstation (Carestream, Rochester, NY, USA). 10 datasets were chosen at random and rescored by the same observer to derive intra-observer agreement.

Statistical methods {#Sec10}
-------------------

Descriptive statistics were used for the analysis of the demographic and clinical features of the cohorts with data expressed as mean ± standard deviation (SD) for normally distributed data, and median (interquartile range) for non-normal distributed data. Normality tests were performed; if the test failed, where possible standard transformations such as square root, reciprocal or logarithmic transforms were used to generate a Gaussian distribution. To test the null hypothesis to determine if samples originate from the same distribution, the one-way analysis of variance (ANOVA) with the Bonferroni post hoc adjustment was used for the parametric data and Kruskal--Wallis ANOVA by ranks was used for the non-parametric data. ANCOVA was performed to confirm differences between the groups with the WB-SAS and LVM used separately as the dependant variables correcting for age, sex, BMI, history of hypertension and smoking status. Two-way random effect absolute agreement single measure intraclass correlation co-efficient (ICC) was performed to assess intra-observer consistency of the WB-SAS and LV metrics. All data were analysed using SPSS statistical package (version 21.0, SPSS Inc. Chicago, IL, USA). Significance was assumed when p \< 0.05. A statistician from the Dundee Epidemiology and Biostatistics Unit (PR) provided statistical support.

Results {#Sec11}
=======

Of the 148 participants who completed the study protocol, 87 (61 %) were male with a mean age was 64 ± 8.2 years (see Table [1](#Tab1){ref-type="table"} for full demographic details). The group with cardiovascular disease and diabetes had a significantly greater proportion of males, while the healthy volunteers had a significantly lower BMI and prevalence of hypertension compared to the other three groups. Other than these there were no statistically significant differences in the demographic metrics between each of the groups. In particular there was no difference in duration of diabetes, or in HbA1c between the diabetic groups with and without history of cardiovascular disease.Table 1Population demographics of the participantsGroup 1 CVD+ DM+Group 2 CVD− DM+Group 3 CVD+ DM−Group 4 CVD− DM−p valueN34553029Male (%)76\*5673410.015Age (years)65 ± 763 ± 867 ± 9\*\*62 ± 80.03BMI (kg/m^2^)31 ± 4\*30 ± 6\*29 ± 428 ± 40.009Hypertension24 (75 %)\*34 (62 %)^**\^**^27 (90 %)\*7 (24 %)\<0.001Systolic BP132 ± 13137 ± 14137 ± 15133 ± 150.4Diastolic BP74 ± 878 ± 876 ± 978 ± 90.25LDL-cholesterol (mmol/l)1.69 ± 0.5\*1.98 ± 0.8\*1.97 ± 0.6\*2.80 ± 0.8\<0.001HDL-cholesterol (mmol/l)1.11 ± 0.3\*1.26 ± 0.3\*1.27 ± 0.51.53 ± 0.40.001Triglycerides (mmol/l)2.08 ± 1.01.70 ± 0.81.60 ± 0.91.76 ± 1.00.18Creatinine86.3 ± 2473.1 ± 1780.7 ± 1770.6 ± 150.003HbA1c7.3 (6--11)**\^**7.3 (5--12)**\^**5.7 (5--8)5.6 (5--6)\<0.001Duration of diabetes (years)10.4 ± 4.79 ± 6.20.3Current/ex smoker (%)724960520.37Medications Antihypertensive therapy (%)84\*\*56\*93\*\*28\<0.001 Number antihypertensive agents1.83 ± 1.0\*\*0.96 ± 1.01.93 ± 0.9\*\*0.39 ± 0.1\<0.001 Statin88\*73\*80\*25\<0.001Prior cardiovascular events^a^ CAD75770.88 Cerebrovascular19230.66 LEAD19170.83Values expressed as mean ± SD, or N (%)Group 1, T2DM and CVD; Group 2, T2DM, no CVD; Group 3, CVD; Group 4, healthy volunteers*BMI* body mass index, *BP* blood pressure, *CAD* coronary artery disease, *LEAD* lower extremity arterial disease\* p \< 0.05 compared to Group 4\*\* p \< 0.05 compared to Groups 2 and 4^\^^p \< 0.05 compared to Groups 3 and 4^a^Groups add up to \>100 % as several individuals had more than one prior cardiovascular event

On WB-MRA analysis, 4564 of the 4588 vessel segments (31 segments in 143 patients) evaluated were graded as 'diagnostic' quality, giving a diagnostic rate of 99.5 %. 24 segments in six examinations were rated as 'non-diagnostic' due to movement artefact or incomplete vessel visualisation. 961 (21.1 %) of the 4564 WB-MRA diagnostic segments had evidence of luminal narrowing: 769 (10.3 %) had stenosis below 50 %, 75 (1.6 %) had stenosis between 50 and 70 %, 60 (1.3 %) had stenosis between 70 and 99 %, and 57 (1.2 %) had complete occlusion. 135 participants (91 %) had evidence of at least one stenotic vessel (Table [2](#Tab2){ref-type="table"}).Table 2Comparison of MRI metrics between the four groupsGroup 1 CVD+ DM+Group 2 CVD− DM+Group 3 CVD+ DM−Group 4 CVD− DM−*p* valueWB-MRA WB SAS4 (0--41.1)\*\*3.23 (0--19.4)10.1 (0--39.5)\*\*2.4 (0--19.4)\<0.001 Head/neck-SAS5.6 (0--11.8)**\^**2.8 (2.8--5.6)5.6 (2.8--9.0)0 (0--5.6)0.024 Aorta-SAS8.3 (0--16.7)0 (0--8.3)16.7 (8.3--16.7)\*\*8.3 (0--8.3)\<0.001 Abdomen-SAS0 (0--10)0 (0--5)5 (0--15)\*0 (0--10)0.02 Ilio-femoral-SAS4.2 (0--22.9)\*4.2 (0--8.3)18.8 (4.2--30.2)\*\*0 (0-10.4)\<0.001 Run off-SAS4.7 (0--19.5)\*\*0 (0--3.1)3.1 (0--25.8)\*\*0 (0--1.6)\<0.001 Normal vessels765\*\*1432627\*\*779\<0.001 Vessels with 1--50 % stenosis190251221\*\*1070.008 Vessels with 51--70 % stenosis38\*\*724\*6\<0.001 Vessels with 71--99 % stenosis24\*426\*\*60.002 Occluded vessels22430\*\*1\<0.001 Abnormal vessels8.5\*\*510.1\*\*4.1\<0.001 N (%) with \>50 % stenosis in any vessel19 (56 %)\*\*12 (21.8 %)20 (66.7 %)\*\*11 (38 %)\<0.001Cardiac MRI LVM (g/m^2^)60.5 (45--86)\*\*54.4 (39--95)60 (41--86)\*\*50.9 (35--73)*0.001* LVEDV (ml/m^2^)71.2 ± 14.566.9 ± 12.874.9 ± 19.868.7 ± 9.90.096 LVESV (ml/m^2^)24.4 (9--58)22.4 (11--55)25.1 (11--90)24.9 (13--38)0.52 LVEF (%)64.6 ± 11.365.9 ± 8.864.3 ± 10.366 ± 7.40.83 LVSV (ml/m^2^)45.3 ± 9.243.7 ± 8.247 ± 8.245.1 ± 7.20.37 LVMVR (g/ml)0.88 ± 0.14**\^**0.84 ± 0.130.83 ± 0.160.78 ± 0.140.036 LVGFI0.43 ± 0.090.45 ± 0.080.44 ± 0.080.47 ± 0.070.21 LGE (%)9 (29)\*3 (5.5)11 (38)\*0 (0)\<0.001Values expressed as mean ± SD, median (range) or N (%)Group 1, T2DM and CVD; Group 2, T2DM, no CVD; Group 3, CVD; Group 4, healthy volunteers*SAS* standardised atheroma score, *WB* whole body, *LVM* left ventricular mass^a^, *EDV* end diastolic volume^a^, *ESV* end systolic volume^a^, *EF* ejection fraction, *SV* stroke volume^a^, *LVMVR* left ventricular mass volume ratio, *LVGFI* left ventricular global function index, *LGE* late gadolinium enhancement\* p \< 0.05 when compared to Group 2\*\* p \< 0.05 when compared to Groups 2 and 4^**\^**^p \< 0.05 when compared to Group 4^a^Normalised to body surface area

Those with cardiovascular disease without diabetes had the highest whole body standardised atheroma score (WB-SAS) of 10.1 (0--39.5) followed by those with cardiovascular disease and diabetes with a WB-SAS of 4 (0--41.1). The normal healthy volunteer group had the lowest WB-SAS of 2.4 (0--19.4), which was slightly lower than those with diabetes but no cardiovascular disease. The WB-SAS of the two cardiovascular groups (Groups 1, 3) was significantly higher than those of the healthy diabetic and healthy control groups (p ≤ 0.05) (Fig. [3](#Fig3){ref-type="fig"}). On univariate analysis of covariance after accounting for age, sex, BMI, history of hypertension and smoking status, the only significant difference that persisted was between the non-diabetic cardiovascular disease group and the healthy controls. There were no significant differences in WB-SAS between the cardiovascular disease groups with and without diabetes, nor between the diabetics without cardiovascular disease and the healthy controls.Fig. 3*Box plot* comparing SAS between the four groups. Group 1, T2DM and CVD; Group 2, T2DM, no CVD; Group 3, CVD; Group 4, healthy volunteers. *Box* 1st--3rd quartiles with *thick line* representing the group median. *Open circle* and *asterisk* outliers

Indexed left ventricular mass (LVM) and prevalence of late gadolinium enhancement was significantly higher in the two cardiovascular disease cohorts (p \< 0.05) compared to both the non-cardiovascular disease groups (see Table [2](#Tab2){ref-type="table"}). Left ventricular mass volume ratio (LVMVR) was significantly higher in the cardiovascular disease group with diabetes compared with the healthy controls but not compared to either of the other two groups. Difference between groups for LVM and LVMVR were lost after accounting for age, sex, BMI, history of hypertension and smoking status on analysis of covariance. There was no significant difference in left ventricular end diastolic volume (EDV) end systolic volume (ESV), stroke volume (SV), ejection fraction (EF) or left ventricular global function index (LVGFI) between the 4 groups. There were no significant differences in any of the LV metrics between subjects with diabetes and those without when history of cardiovascular disease was accounted for.

Left ventricular myocardial contrast enhancement was observed in 29 % of type 2 diabetic with CVD (Group 1), 5.5 % of type 2 diabetic without CVD (Group 2), 39 % of non-diabetics with CVD (Group 3), and 0 % of non-diabetics with no CVD (Group 4) (Table [2](#Tab2){ref-type="table"}). Clinical records showed that all 11 non-diabetic Group 3 subjects with positive LGE had a history of coronary heart disease. However only eight of the nine diabetic Group 1 subjects had a history of coronary heart disease, with one reporting known LEAD but no previous history of coronary artery disease in keeping with a silent myocardial infarct. 3 (5.5 %) participants with diabetes without any history of cardiac event demonstrated myocardial scarring typical of a myocardial infarction, the whole body SAS of these three individuals was significantly higher than the remainder of the diabetes group without history of cardiovascular disease \[7.7 (4--19) vs. 2.8 (0--17), p = 0.024\].

Both SAS and the LV metrics demonstrated good agreement on intra-observer analysis: SAS ICC 0.93 (95 % CI 0.83--0.97, p \< 0.001); EF ICC 0.98 (95 % CI 0.85--0.99, p \< 0.001); EDV ICC 0.98 (95 % CI 0.56--0.99, p \< 0.001), SV ICC 0.98 (95 % CI 0.92--0.99, p \< 0.001); LVM ICC 0.99 (95 % CI 0.98--0.99, p \< 0.001). This is consistent with previous work where intra- and interobserver variability for both readers and techniques has been described in more detail \[[@CR7]\].

Intra-observer variability was good for the WB-SAS (0.93 (95 % CI 0.83--0.97, p \< 0.001).

Discussion {#Sec12}
==========

In this study we have shown that in non-diabetics the global atheroma burden as measured by whole body MRA is significantly higher in individuals with clinically evident cardiovascular disease compared with diabetic and non-diabetic controls. However when looking at those with type 2 diabetes there was significant overlap in the atheroma burden between the groups with and without cardiovascular disease, and no significant difference between either groups compared with healthy controls. This is a surprising and, given the known effects of diabetic status on cardiovascular events, a slightly counterintuitive finding.

From the current observations it appears that either cardiovascular events occur at a lower atheroma burden in those with type 2 diabetes compared with non-diabetics, or that there is a clinical bias in the suspicion of vascular events in those with type 2 diabetes resulting in diagnosis of cardiovascular events at a lower disease threshold. Atherosclerotic plaques in those with diabetes have a larger necrotic core, a thinner capsule and impaired vascular repair mechanisms---all of which increase the likelihood of rupture \[[@CR15]--[@CR17]\]. Given that the majority of coronary and cerebrovascular events occur secondary to ruptured atherosclerotic plaque \[[@CR18], [@CR19]\], it is therefore feasible that cardiovascular events occur at a lower atheroma burden in a diabetic population due to a greater propensity of the plaques they do have of rupturing and occluding arteries. In addition diabetes is associated with impaired microcirculatory function, which itself is associated with a higher risk for future cardiovascular events, therefore potentially reducing the atheroma burden necessary to elicit a cardiovascular event \[[@CR20], [@CR21]\].

A previous study using whole body atheroma burden by Weckbach et al. \[[@CR22]\] demonstrated an increased burden of vascular disease in a diabetic cohort compared with a healthy population. However given that the diabetic group included patients with cardiovascular disease while their control group excluded patients with cardiovascular disease it is difficult to extricate the effects of diabetes per se on atheroma burden, especially given that in our study we found a higher burden of atheroma in those with cardiovascular disease compared to those without. A separate subgroup analysis by the same group showed that those with diabetes with metabolic syndrome had a significantly higher atheroma burden than those without, but did not compare those with diabetes but without metabolic syndrome to the healthy cohort \[[@CR8]\]. In a population based study of 306 70-year-old Hansen et al. found no association between diagnosis of diabetes and atheroma burden, however found a relationship between the HOMA insulin resistance index and atheroma score \[[@CR23]\]. Lehrke et al. \[[@CR24]\] also found no difference in atheroma burden between diabetic and non-diabetic groups, although the study only had 13 diabetic patients in their cohort. Consistent with these previous studies we have found that when diabetic patients are compared with patients without diabetes after stratifying them based on cardiovascular history that no difference in atheroma burden was observed. A similar lack of difference in stenotic atheroma burden has been observed on invasive coronary angiography between groups with and without type 2 diabetes \[[@CR25], [@CR26]\].

While our criteria for recruitment into the cardiovascular disease groups was strict it does not preclude the effects of referral bias in the type 2 diabetes cohort. Given the known increased cardiovascular risk in type 2 diabetes it is possible that the threshold for eliciting a referral for cardiovascular related investigations for symptomatology occurs at an earlier stage in those with diabetes than those without thus resulting in a lower observed atheroma burden. Greater prescription of antihypertensive and statin therapy was observed in both the groups with diabetes compared with the healthy controls, which if initiated early in the disease processes could also have attenuated disease progression given the known effects of statins on plaque volume \[[@CR27]\].

Less likely is that the lack of difference in observed atheroma burden between the groups may lie in the lumenographic assessment that WB-MRA provides, with lack of ability to quantify non stenotic atheroma with positive remodelling. When considering coronary artery disease, catheter angiography has demonstrated no significant difference between diabetic and non-diabetic cohorts in stenotic disease burden \[[@CR25], [@CR26]\], however when intravascular ultrasound is used a greater plaque area encasing diffusely narrower arteries is observed \[[@CR28]\]. Also CT coronary artery calcium scoring and CT coronary angiography, which can visualise extraluminal plaque, demonstrate higher plaque burden in diabetic cohorts \[[@CR29]\]. The lumenographic nature of the technique is an acknowledged limitation \[[@CR30]\], however no other widely available technique is yet available to quantify this metric throughout the entire body. Furthermore, atherosclerosis with positive vascular remodelling is a relatively early phenomenon in the development of plaque, therefore even if this were to be missed it would not explain the discrepancy in stenotic plaque burden.

Within the healthy diabetic cohort we observed a 5 % prevalence of silent myocardial infarct. This is in keeping with prior studies showing an incidence of silent infarcts in diabetic populations to range from 2.7 to 17 % depending on the method used and cohort studied \[[@CR31]--[@CR33]\]. Those with silent myocardial infarcts had a significantly higher atheroma burden which is consistent with other groups results showing that those with an elevated atheroma burden were more likely to have obstructive coronary artery disease and develop major adverse cardiovascular events at follow-up \[[@CR9], [@CR24]\]. This finding adds further support of the prognostic importance of the whole body atheroma burden on future cardiovascular events as evidenced by two prior studies showing the stenotic atheroma burden on WB-MRA to have superior prognostic efficacy over traditional risk scores, carotid intima media thickness and ankle-brachial pressure index \[[@CR9], [@CR34]\].

There are several limitations of the current study. As previously discussed whole body MRA is a lumenographic technique, and therefore may miss plaque with vascular remodelling which maintains the luminal diameter. Our scoring system prescribes no weighting to specific vessels, or to vessels with multisite stenosis. Long-term studies are required to assess the prognostic significance of disease of individual vessels, and how multiple lesions compare with single lesions in these different groups. Finally the coronary vessels are not assessed in the current study protocol. MRI coronary angiography holds some promise but is still some way off routine clinical use \[[@CR35]\], however as this continues to improve incorporation of this in WB-CVMR will become an interesting avenue for exploration in the future.

Conclusion {#Sec13}
==========

Global atheroma burden was significantly higher in those with known cardiovascular disease and without diabetes but not in those with diabetes and cardiovascular disease suggesting that cardiovascular events may occur at a lower atheroma burden in diabetes.

Additional file {#Sec14}
===============

[**Additional file 1: Table S1.**](http://www.cardiab.com/content/supplementary/s12933-015-0284-2-S1.docx) Breakdown of the inclusion criteria for each of the cardiovascular disease territories.
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